News from seqirus A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
Latest
Dec 09, 2020, 08:30 ET Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020
Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) at the European Scientific Working Group on Influenza ...
Dec 07, 2020, 08:30 ET Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity of Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine
Seqirus, a global leader in influenza prevention and influenza pandemic response, today announced the presentation of new data at the European...
Dec 07, 2020, 08:00 ET Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Benefits of MF59®-Adjuvanted Seasonal Influenza Vaccine
Seqirus, a global leader in influenza prevention and influenza pandemic response, today announced new late-breaking data from a systematic review and ...
Oct 29, 2020, 12:00 ET Seqirus Presents First-of-its-Kind Study on Cell-Based Quadrivalent Influenza Vaccine (QIVc) Efficacy in Children ≥2 to <18 Years Old at the European Society for Paediatric Infectious Diseases (ESPID)
Seqirus, a global leader in influenza prevention, today presented absolute efficacy data on the company's cell-based quadrivalent influenza vaccine...
Oct 21, 2020, 09:00 ET Seqirus Presents New Real-World Evidence on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older at IDWeek 2020
Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) on the effectiveness of an MF59®-adjuvanted,...
Oct 21, 2020, 08:00 ET Seqirus Announces Late-Breaking Data at IDWeek 2020: New Real-World Evidence Shows Value of Adjuvanted Influenza Vaccine for Adults 65 Years and Older with Underlying Health Conditions
Seqirus, a global leader in influenza prevention, today announced new, late-breaking real-world evidence (RWE) to be presented at IDWeek 2020...
Sep 21, 2020, 08:30 ET Seqirus Publishes New Real-World Evidence (RWE) on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Vaccines
Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) that demonstrated an MF59®...
Sep 16, 2020, 08:30 ET Seqirus Real World Evidence Published in Vaccine Highlights Value of Cell-Based Quadrivalent Influenza Vaccine in Preventing Influenza Related Hospitalizations in the U.S. 2017/18 Season
Seqirus, a global leader in influenza prevention, today announced the publication of real-world evidence (RWE) on the company's cell-based...
Jul 30, 2020, 08:00 ET Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market
Seqirus has started shipping its portfolio of seasonal influenza vaccines to United States (U.S.) customers for the upcoming 2020/21 U.S. influenza...
Feb 24, 2020, 08:30 ET Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older
Quadrivalent formulation of the first-and-only adjuvanted seasonal influenza vaccine for older adults (65+ years) receives FDA approval1 Designed...
Feb 03, 2020, 08:30 ET Seqirus Announces U.S. FDA Approval of Its First-Ever Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine
Seqirus, a global leader in influenza prevention and pandemic response, today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Dec 09, 2019, 09:00 ET New Data Demonstrate that FLUAD® (Influenza Vaccine, Adjuvanted) Significantly Reduces Hospitalization Risk for Adults 65+ Living in U.S. Nursing Homes Compared to Standard Trivalent Influenza Vaccine
Seqirus announced today results from a prospective, cluster-randomized trial led by a team of researchers from Brown University that showed FLUAD®,...
Sep 26, 2019, 10:55 ET Seqirus Applauds the Executive Order to Accelerate Enhanced Protection Against Influenza Threats
Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, applauds the Administration for recognizing the urgency of ensuring...
Aug 31, 2019, 08:30 ET Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X)...
Aug 30, 2019, 08:30 ET Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response
Seqirus, a global leader in influenza prevention, today presented data at the Options for the Control of Influenza (OPTIONS X) Conference in...
Aug 22, 2019, 08:30 ET Seqirus to Present Data on Pandemic and Seasonal Influenza Vaccines at OPTIONS X Conference
Seqirus, a global leader in influenza prevention, today announced it will feature data in 3 presentations and 24 posters on the company's adjuvant...
Jul 17, 2019, 08:30 ET Anjana Narain to Lead Seqirus Influenza Vaccines Business
CSL Limited today named Anjana Narain, a seasoned leader in vaccines and biopharmaceuticals, as Executive Vice President and General Manager of its...
Jul 15, 2019, 08:30 ET Seqirus is First-to-Market with U.S. 2019/20 Influenza Vaccines
Seqirus is first to begin shipping its portfolio of seasonal influenza vaccines for the upcoming 2019/20 U.S. influenza season Seqirus plans to...
Apr 15, 2019, 08:30 ET Seqirus Announces Further Advances in Cell-Based Influenza Vaccine Technology
Seqirus, a leading innovator in influenza protection, today announced it will file an Annual Strain Update with the U.S. Food and Drug Administration ...
Nov 16, 2018, 09:00 ET Seqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines
Seqirus, a wholly owned subsidiary of CSL Limited and a global leader in influenza prevention, today announced a $140M expansion of its Holly Springs ...
Nov 16, 2018, 08:00 ET Seqirus Releases Real-World Data Indicating Significantly Greater Effectiveness of Cell-Based Seasonal Influenza Vaccines Compared to Standard Influenza Vaccine Options
Seqirus, a global leader in influenza prevention, today released a new real-world evidence analysis indicating that its cell-based quadrivalent...
Oct 23, 2018, 08:01 ET Seqirus Receives FDA Approval of AFLURIA® QUADRIVALENT (Influenza Vaccine) for People Six Months of Age and Older in the U.S.
Seqirus, a global leader in influenza prevention, today announced the U.S. Food and Drug Administration (FDA) has approved AFLURIA® QUADRIVALENT...
Oct 03, 2018, 17:02 ET Seqirus Presents Data at IDWeek Demonstrating Cell-Derived Viruses Have a Closer Match to Circulating Influenza Viruses Compared to Egg-derived Viruses Used in the Production of Influenza Vaccines
Seqirus, a global leader in influenza prevention, today announced data, to be presented at IDWeek 2018 on Saturday, October 6, showing that higher...
Oct 03, 2018, 16:45 ET Seqirus Presents Favorable Outcomes Data for Adjuvanted Trivalent Influenza Vaccine (FLUAD®) at 6th Annual IDWeek
Seqirus, a global leader in influenza prevention, will present new healthcare and cost outcomes data for its MF59®-adjuvanted trivalent influenza...
Aug 23, 2018, 09:23 ET Seqirus secures FDA approval for next generation cell-based influenza vaccine manufacturing process
Seqirus, a global leader in influenza vaccine innovation, today announced FDA approval of its next generation cell-based manufacturing process at...
